Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology CongressGlobeNewsWire • 09/17/25
Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough AwardGlobeNewsWire • 09/16/25
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/25
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5GlobeNewsWire • 09/03/25
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?Zacks Investment Research • 09/01/25
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/27/25
Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-RateSeeking Alpha • 08/23/25
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should KnowZacks Investment Research • 08/14/25
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/06/25
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/25
Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline ExpansionSeeking Alpha • 08/01/25
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025GlobeNewsWire • 07/23/25
Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196%Investors Business Daily • 07/17/25
Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic DermatitisGlobeNewsWire • 06/26/25
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic DermatitisGlobeNewsWire • 06/10/25
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis ConferenceGlobeNewsWire • 06/06/25
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 05/29/25